AGN-151586 Dose-Ranging Study for Treatment of Glabellar Lines

A Phase 2b Double-Blind, Placebo-Controlled, Dose-Ranging Study to Evaluate the Safety and Efficacy of AGN-151586 in Participants With Moderate to Severe Glabellar Lines

The purpose of this study is to evaluate the safety and efficacy of AGN-151586 over a range of doses for the treatment of moderate to severe glabellar lines (GL).

Study Overview

• Status: Completed
• Conditions: Glabellar Lines
• Intervention / Treatment: Drug: Placebo; Drug: AGN-151586

• Study Type: Interventional
• Enrollment (Actual): 198
• Phase: Phase 2

Contacts and Locations

Study Locations

• United States
  • California
    • Fremont, California, United States, 94538
      • Center for Dermatology Clinical Research /ID# 237798
    • Santa Monica, California, United States, 90404-2208
      • Ava T. Shamban MD - Santa Monica. /ID# 235353
  • Florida
    • Miami, Florida, United States, 33137-3254
      • Skin and Cancer Associates, LLP /ID# 236231
  • Indiana
    • Indianapolis, Indiana, United States, 46260-2386
      • Laser and Skin Surgery Center of Indiana /ID# 236588
  • North Carolina
    • Wilmington, North Carolina, United States, 28403
      • Wilmington Dermatology Center /ID# 237055
  • Pennsylvania
    • Newtown Square, Pennsylvania, United States, 19073-2228
      • Kgl, Llc /Id# 234798
  • Texas
    • Austin, Texas, United States, 78759
      • DermResearch Inc. /ID# 234483
    • Houston, Texas, United States, 77056-4129
      • Austin Institute for Clinical Research at SBA Dermatology /ID# 236646
    • Pflugerville, Texas, United States, 78660
      • Austin Institute for Clinical Research /ID# 237135

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years to 65 years (Adult, Older Adult)
• Accepts Healthy Volunteers: No

Description

Inclusion Criteria:

-Female participants willing to minimize the risk of inducing pregnancy for the duration of the clinical study and follow-up period (at least 10 weeks after study intervention).

Exclusion Criteria:

• Known immunization or hypersensitivity to any botulinum neurotoxin serotype
• Any medical condition that may put the participant at increased risk with exposure to AGN-151586, including diagnosed myasthenia gravis, Eaton-Lambert syndrome, amyotrophic lateral sclerosis, or any other condition that might interfere with neuromuscular function
• Marked facial asymmetry, dermatochalasis, deep dermal scarring, excessively thick sebaceous skin, or the inability to substantially lessen facial lines even by physically spreading them apart, as determined by the investigator
• Any brow or eyelid ptosis, as determined by the investigator
• Infection or skin disorder at the injection sites
• History of facial nerve palsy
• Any uncontrolled systemic disease
• Anticipated need for treatment with botulinum neurotoxin of any serotype for any reason during the study (other than study intervention)
• Anticipated need for surgery or overnight hospitalization during the study
• Prior periorbital surgery, facial lift (full face or mid-face), thread lift, brow lift, or related procedures (eg, eyelid [blepharoplasty] and/or eyebrow surgery)
• Prior facial treatment with permanent soft tissue fillers, synthetic implantation (eg, Gore-Tex®), and/or autologous fat transplantation
• Current enrollment in an investigational drug or device study or participation in such a study within 30 days of Screening

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: Triple

Number of Arms

10

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Placebo Comparator: Cohort 1: Placebo; Participants received AGN-151586-matching placebo, intramuscular (IM) injections in the glabellar complex on Day 1 in Cohort 1.	Drug: Placebo; Placebo solution for injection.
Experimental: Cohort 1: AGN-151586; Participants received AGN-151586 lowest dose, IM injections in the glabellar complex on Day 1.	Drug: AGN-151586; AGN-151586 solution for injection.
Placebo Comparator: Cohort 2: Placebo; Participants received AGN-151586-matching placebo, IM injections in the glabellar complex on Day 1 in Cohort 2.	Drug: Placebo; Placebo solution for injection.
Experimental: Cohort 2: AGN-151586; Participants received AGN-151586, IM injections in the glabellar complex on Day 1.	Drug: AGN-151586; AGN-151586 solution for injection.
Placebo Comparator: Cohort 3: Placebo; Participants received AGN-151586-matching placebo, IM injections in the glabellar complex on Day 1 in Cohort 3.	Drug: Placebo; Placebo solution for injection.
Experimental: Cohort 3: AGN-151586; Participants received AGN-151586, IM injections in the glabellar complex on Day 1.	Drug: AGN-151586; AGN-151586 solution for injection.
Placebo Comparator: Cohort 4: Placebo; Participants received AGN-151586-matching placebo, IM injections in the glabellar complex on Day 1 in Cohort 4.	Drug: Placebo; Placebo solution for injection.
Experimental: Cohort 4: AGN-151586; Participants received AGN-151586, IM injections in the glabellar complex on Day 1.	Drug: AGN-151586; AGN-151586 solution for injection.
Placebo Comparator: Cohort 5: Placebo; Participants received AGN-151586-matching placebo, IM injections in the glabellar complex on Day 1 in Cohort 5.	Drug: Placebo; Placebo solution for injection.
Experimental: Cohort 5: AGN-151586; Participants received AGN-151586 highest dose, IM injections in the glabellar complex on Day 1.	Drug: AGN-151586; AGN-151586 solution for injection.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Percentage of Participants With ≥ 2-grade Improvement From Baseline on the FWS According to Investigator's Assessment at Any Postintervention Timepoint Through Day 7	Percentage of participants achieving a ≥ 2-grade improvement from baseline on the FWS according to investigator assessments of GL severity at maximum frown at any postintervention timepoint through Day 7 were reported. Investigators' assessments of the severity of GL at rest and maximum frown using the validated FWS was assessed using the 4-grade FWS, where 0=none, 1=mild, 2=moderate, and 3=severe. Higher scores indicate more severity. Percentages are rounded off to nearest single decimal.	Baseline (Day 1) through Day 7
Number of Participants Who Experience One or More Treatment Emergent Adverse Events (TEAEs)	An adverse event (AE) was defined as any untoward medical occurrence in a participant or clinical study participant, temporally associated with the use of study intervention, whether considered related to the study intervention or not. TEAEs were defined as events event began on or after the date and time of the study intervention; or the adverse event was present before the date and time of the study intervention, but increased in severity or became serious on or after the date and time of the study intervention.	From first dose of study drug until the end of study (up to 42 days)
Number of Participants With Potentially Clinically Significant Laboratory Parameters Post Intervention	Potentially clinically significant post intervention laboratory values included hematology, chemistry, and urinalysis as defined in the SAP.	From first dose of study drug until the end of study (up to 42 days)
Number of Participants With Potentially Clinically Significant Vital Signs Post Intervention	Potentially clinically significant post intervention vital sign measurements included systolic and diastolic blood pressure, pulse rate, respiration rate, body temperature as defined in the SAP.	From first dose of study drug until the end of study (up to 42 days)
Number of Participants With Potentially Clinically Significant Electrocardiogram Findings Post Intervention	Potentially clinically significant post intervention values in 12-lead ECG recordings included heart rate and measures PR, QRS, QT and QTcF intervals. 12-lead ECG recordings were obtained after the participants have rested for at least 10 minutes in semi-supine or supine position as defined in the SAP. A post-baseline value is considered potentially clinically significant if it meets either the observed-value or the change-from-baseline criteria such as QRS interval observed value: ≥ 150 msec; PR interval observed value: ≥ 250 msec; QTcB observed value: > 500 msec or change from baseline value: increase of > 60 msec; QTcF observed value: > 500 msec or change from baseline value: increase of > 60 msec.	From first dose of study drug until the end of study (up to 42 days)
Number of Participants With Anti-drug Antibodies (ADAs)	Number of participants with positive anti-drug antibodies are reported. Binding and neutralizing anti-bodies are evaluated as anti-drug antibodies. Only participants with positive samples for binding antibodies have been analyzed for presence of neutralizing antibodies.	Up to Day 42

Collaborators and Investigators

• Sponsor: Allergan
• Investigators: Study Director: ALLERGAN INC., Allergan

Publications and helpful links

Helpful Links

• Additional information on study locations near you may be found at AllerganClinicalTrials.com. For any study not on AllerganClinicalTrials.com, please contact IR-CTRegistration@Allergan.com for assistance

Study record dates

Study Major Dates

• Study Start (Actual): September 26, 2019
• Primary Completion (Actual): September 9, 2020
• Study Completion (Actual): September 9, 2020

Study Registration Dates

• First Submitted: September 4, 2019
• First Submitted That Met QC Criteria: September 18, 2019
• First Posted (Actual): September 19, 2019

Study Record Updates

• Last Update Posted (Actual): July 28, 2023
• Last Update Submitted That Met QC Criteria: July 10, 2023
• Last Verified: July 1, 2023

More Information

Terms related to this study

• Other Study ID Numbers: 2034-201-008

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: YES
• IPD Plan Description: AbbVie is committed to responsible data sharing regarding the clinical trials we sponsor. This includes access to anonymized, individual and trial-level data (analysis data sets), as well as other information (e.g., protocols, analyses plans, clinical study reports), as long as the trials are not part of an ongoing or planned regulatory submission. This includes requests for clinical trial data for unlicensed products and indications.
• IPD Sharing Time Frame: For details on when studies are available for sharing visit https://vivli.org/ourmember/abbvie/
• IPD Sharing Access Criteria: Access to this clinical trial data can be requested by any qualified researchers who engage in rigorous independent scientific research, and will be provided following review and approval of a research proposal and statistical analysis plan and execution of a data sharing statement. Data requests can be submitted at any time after approval in the US and/or EU and a primary manuscript is accepted for publication. For more information on the process, or to submit a request, visit the following link https://www.abbvieclinicaltrials.com/hcp/data-sharing/
• IPD Sharing Supporting Information Type: STUDY_PROTOCOL; SAP; CSR

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: Yes
• Studies a U.S. FDA-regulated device product: No
• product manufactured in and exported from the U.S.: Yes